Core Insights - Sibylla Biotech has appointed Dieter Weinand as Chairman of its Board of Directors, bringing over 35 years of experience in the pharmaceutical sector [1][4] - The company aims to advance its innovative PPI-FIT technology and pipeline of folding interference small molecules to address challenging therapeutic areas [1][3] Company Overview - Sibylla Biotech is focused on transforming drug discovery by targeting protein folding intermediates, which represents a new druggable dimension in pharmacology [6] - The proprietary PPI-FIT technology allows the company to predict and target intermediate steps in the protein folding process, leading to targeted protein degradation [6][7] Leadership Background - Dieter Weinand has a distinguished career, having held significant roles at major pharmaceutical companies such as Bayer Pharmaceuticals AG, Sanofi, Bristol-Meyers Squibb, and Pfizer [4][5] - His leadership experience includes overseeing the integration of R&D, manufacturing, and commercial functions, contributing to the launch of several high-impact medicines [4] Strategic Vision - The appointment of Mr. Weinand is seen as a strategic move to unlock access to previously undruggable targets and drive the next stages of Sibylla's growth [2][3] - The company is building a pipeline of treatments for high medical need diseases across multiple therapeutic areas, with a mission to bring protein folding interference therapeutics to patients [7]